Breaking News

House E&C Committee Passes Two Bills That Would Create 340B Entity Reporting Requirements

Energy & Commerce Committee
The House E&C Committee passed a bill to impose reporting requirements on 340B DSH hospitals and potentially other entities. The committee passed another bill that could expose all types of 340B covered entities to separate reporting requirements.

The House Energy & Commerce Committee passed two bills today to impose 340B program reporting requirements on hospitals and other health care providers.

They were among 19 health care, telecommunications, and energy bills that the committee marked up today.

Read More »

House E&C Committee to Vote Tomorrow on Bills That Would Bring Big Changes to 340B

House E&C Committee
The House E&C Committee tomorrow will markup two bills that 340B providers are watching very closely.

340B provider groups won some concessions on controversial Medicaid managed care drug billing language that the full U.S. House Energy & Commerce Committee is marking up tomorrow, lobbyists say. Efforts to get more changes continue.

The committee announced late

Read More »

Health Centers’ Antitrust Case Over 340B Contract Pharmacy Limits Will be Argued July 20

Federal District Court Rochester
There will be a federal district court hearing July 20 in Rochester, N.Y., in two health centers' 340B-related antitrust suit against insulin and diabetes drug makers.

A once-dead lawsuit that accuses drug makers of colluding to deny 340B pricing on insulin and diabetes drugs shipped to contract pharmacies is going to be heard July 20 in federal district court in Rochester, N.Y.

Chief Judge Elizabeth Wolford

Read More »

Providers Added Immediately to 340B Under COVID-19 Flexibility Are Not Losing their Eligibility, HRSA Confirms

HRSA OPA homepage
HRSA confirmed that providers granted immediate 340B enrollment under a COVID-19 flexibility are not losing their 340B eligibility and will not need to re-enroll. HRSA recently posted a notice about those enrollments on the OPA homepage.

Federal 340B program officials confirmed last week that providers granted immediate 340B enrollment under a COVID-19 public health emergency flexibility are not losing their 340B eligibility and will not need to re-enroll now that the PHE is over.

The U.S.

Read More »

Bills Filed in New York to Help 340B Providers Hurt by Medicaid Drug Benefit Transfer

Gustavo Rivera
New York State Sen. Gustavo Rivera (D) introduced bills to help 340B providers hurt by the state’s transfer of Medicaid managed care drug benefits to Medicaid fee for service on April 1.

A New York state lawmaker and strong 340B program supporter last week introduced bills to help 340B providers hurt by the state’s transfer of Medicaid managed care drug benefits to Medicaid fee for service on April 1.

Under Medicaid managed

Read More »

In “Nasty Surprise,” House Subcommittee Votes to Require Billing Medicaid MCOs at Cost Plus Dispensing Fee for Drugs, Including 340B

Energy & Commerce Health
The U.S. House E&C health subcommittee yesterday unexpectedly passed a bill 27-0 with language that would make it impossible nationally for 340B entities to earn revenue from billing state Medicaid managed care plans above what they pay for 340B-acquired drugs.

340B covered entity representatives are scrambling to respond to a U.S. House subcommittee’s unanimous approval yesterday of a bill that includes language that would make it impossible nationally for entities to earn revenue from billing state Medicaid managed care contractors

Read More »

House E&C Full Committee May Vote on 340B Transparency Bill as Soon as Next Week

Pallone
House E&C full committee ranking Democrat Frank Pallone said yesterday that 340B hospital reporting legislation the E&C health subcommittee passed yesterday "may be used to draw an inaccurate narrative about the value of the program.”

The full House Energy & Commerce Committee as of late this morning had not yet said when it will markup 340B hospital reporting legislation that split its health subcommittee in two along party lines yesterday. The committee’s Republican majority reportedly

Read More »

Amgen and GSK Announce Refunds for 340B Overcharges

Nucala
GlaxoSmithKline is providing refunds for overcharges during Q2 2021 on sales of two NDCs of its severe asthma medicine Nucala.

Drug manufacturers Amgen and GlaxoSmithKline have notified 340B covered entities about refunds for overcharges, Amgen for sales in 2020 and GSK for sales in 2021.

The U.S. Health Resources and Services Administration posted both companies’ notices on its website yesterday.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report